- Home
- Companies
- W. L. Gore & Associates, Inc.
- Products
- Gore - Propaten Vascular Graft
Gore - Propaten Vascular Graft
Addressing the problem of thrombus formation on the luminal surface of a vascular graft is a challenge faced by all vascular surgeons. The GORE PROPATEN Vascular Graft is specifically designed for those vascular procedures in which the risk of acute graft thrombotic failure is of clinical concern.
The GORE® PROPATEN® Vascular Graft harnesses the anticoagulant properties of heparin directly at the luminal surface of the graft. The proprietary end-point attachment mechanism, the CBAS Heparin Surface, serves to anchor heparin molecules to the luminal surface while still maintaining heparin`s intrinsic bioactive properties. The result: a thromboresistant bioactive graft surface that retains its bioactive properties.1
The GORE® PROPATEN® Vascular Graft has demonstrated improved thromboresistance and patency compared to standard ePTFE grafts in pre-clinical in vivo tests. A randomized, multi-center clinical study has shown promising results.2 The thromboresistant surface technology employed on the GORE® PROPATEN® Vascular Graft is designed to maintain bioactivity, thus increasing the potential for performance improvement and increased patency*.
The BioActive luminal surface of a 3 mm diameter GORE® PROPATEN® Vascular Graft (top) remains free of thrombus, while the non-bioactive surface of a control graft (below; 3 mm diameter) is covered with thrombus. Grafts were explanted after 2 hours in a challenging carotid shunt canine model.
Innovation for Improved Outcomes in Complex Peripheral Disease
Gore`s innovative solutions are designed for treating complex peripheral disease and backed by dedicated service to help improve patient outcomes.
